2026-04-17T20:11:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/38582025-10-24T10:34:57Zcom_2072_378070com_2072_378040col_2072_378092

Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy Diaz, Montserrat Agraz Pamplona, Irene Soler Romeo, Maria Jose Institut Català de la Salut [Diaz M] Nephrology Department, Hospital Universitari Fundació Puigvert. Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Agraz I, Soler MJ] Servei de Nefrologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Vall d'Hebron Barcelona Hospital Campus Glomerulonefritis Fosfolipases - Immunologia DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Glomerulonephritis::Glomerulonephritis, Membranous Other subheadings::Other subheadings::Other subheadings::/immunology DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression::Remission, Spontaneous CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Carboxylic Ester Hydrolases::Phospholipases::Phospholipases A::Phospholipases A2 ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::glomerulonefritis::glomerulonefritis membranosa Otros calificadores::Otros calificadores::Otros calificadores::/inmunología ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad::remisión espontánea COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::hidrolasas::esterasas::éster carboxílico hidrolasas::fosfolipasas::fosfolipasas A::fosfolipasas A2 Anti-phospholipase A2 receptor antibody; Membranous nephropathy; Spontaneous remission Anticòs del receptor anti-fosfolipasa A2; Nefropatia membranosa; Remissió espontània Anticuerpo del receptor anti-fosfolipasa A2; Nefropatía membranosa; Remisión espontánea Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in native kidney biopsies from adults. In 2009, antibodies to the M-type receptor of phospholipase A2 (anti-PLA2R) were identified in idiopathic MN patients, both within the kidney and in the circulation. The clinical course of idiopathic MN is variable and ranges from spontaneous remission to end-stage renal disease. Clinical variables such as proteinuria levels, patient sex, age and renal function at diagnosis have been associated with renal MN progression. In this editorial, we update the importance of anti-PLA2R levels as a prognostic marker in idiopathic MN at the diagnosis of the disease 2019-03-22T12:53:47Z 2019-03-22T12:53:47Z 2019-02-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Diaz M, Agraz I, Soler MJ. Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy. Clin Kidney J. 2019;12(1):33–5. 2048-8505 https://hdl.handle.net/11351/3858 10.1093/ckj/sfy079 30747149 http://hdl.handle.net/11351/3858 eng Clinical Kidney Journal;12(1) https://academic.oup.com/ckj/article/12/1/33/5114409 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Oxford University Press Scientia